MedTrace Logo

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

NCT06081166 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-05-22

No results posted yet for this study

Summary

A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin

Conditions

  • Healthy Volunteers

Interventions

DRUG

Obicetrapib

obicetrapib 10 mg daily

DRUG

Atorvastatin Calcium

Atorvastatin 80 mg

DRUG

Rosuvastatin Calcium

Rosuvastatin 40 mg

Sponsors & Collaborators

  • Pharma Medica Research, Inc.

    collaborator INDUSTRY

  • NewAmsterdam Pharma

    lead INDUSTRY

Principal Investigators

  • Mark M Feldman · Pharma Medica Research, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-11
Primary Completion
2023-12-02
Completion
2024-01-22
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081166 on ClinicalTrials.gov